References
- Mash DC. Breaking the cycle of opioid use disorder with Ibogaine. Am J Drug Alcohol Abuse. 2018;44(1):1–3. 2018/01/02.
- Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat. 1994 Jul-Aug;11(4):379–385. PubMed PMID: 7966509.
- Obach RS, Pablo J, Mash DC. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998 Aug;26(8):764–768. PubMed PMID: 9698290.
- Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015 Jan 29;20(2):2208–2228. PubMed PMID: 25642835; PubMed Central PMCID: PMCPMC4382526.
- Welsch L, Bailly J, Darcq E, et al. The Negative Affect of Protracted Opioid Abstinence: progress and Perspectives From Rodent Models. Biol Psychiatry. 2020 Jan 1;87(1):54–63. PubMed PMID: 31521334; PubMed Central PMCID: PMCPMC6898775.
- Staley JK, Ouyang Q, Pablo J, et al. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology (Berl). 1996 Sep;127(1):10–18. PubMed PMID: 8880938.
- Belgers M, Leenaars M, Homberg JR, et al. Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Transl Psychiatry. 2016 May 31;6(5):e826. PubMed PMID: 27244235; PubMed Central PMCID: PMCPMC5545647.
- Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008 Jan 4;115(1):9–24. . PubMed PMID: 18029124.
- Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. PubMed PMID: 28402682 Am J Drug Alcohol Abuse. 2018;441:37–46.
- Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. PubMed PMID: 28541119 Am J Drug Alcohol Abuse. 2018;441:24–36.
- Malcolm BJ, Polanco M, Barsuglia JP. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. J Psychoactive Drugs. 2018 Jul-Aug;50(3):256–265. . PubMed PMID: 29608409.
- Mazoyer C, Carlier J, Boucher A, et al. Fatal case of a 27-year-old male after taking iboga in withdrawal treatment:GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. J Forensic Sci. 2013 Nov;58(6):1666–1672. PubMed PMID: 23919354.
- Corkery JM. Ibogaine as a treatment for substance misuse: potential benefits and practical dangers. Prog Brain Res. 2018;242:217–257. PubMed PMID: 30471681. .
- Acimovic T, Atanasijevic T, Denic K, et al. Death due to consumption of ibogaine: case report. Forensic Sci Med Pathol. 2021 Jan 12 PubMed PMID: 33433774. https://doi.org/10.1007/s12024-020-00342-0.
- Bouso JCF, I., Vilamala MV, et al. An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers. Archives of Clinical Psychiatry (São Paulo). 2020;47: 51–54.
- Grogan J, Gerona R, Snow JW, et al. Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. J Emerg Med. 2019 Oct;57(4):e99–e104. PubMed PMID: 31630892.
- Henstra M, Wong L, Chahbouni A, et al. Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clin Toxicol (Phila). 2017 Jul;55(6):600–602. PubMed PMID: 28489458.
- Yip L, Deng JF. On the toxicity of ibogaine. Clin Toxicol (Phila). 2016 Aug;54(7):605. . PubMed PMID: 27243473.